ArrowMark Partners

Frontier Medicines Corporation is a pre-clinical stage biopharmaceutical company based in South San Francisco, California, founded in 2018. The company focuses on the discovery and development of medicines targeting cancer-causing proteins through its innovative chemoproteomics platform. This platform utilizes advanced computational methods and machine learning to identify and pharmacologically target new binding pockets on proteins, facilitating the development of small-molecule drugs. By enhancing the accessibility of these proteins, Frontier Medicines aims to provide effective treatments that can redefine the management of debilitating diseases.

SmartLabs specializes in designing, building, and operating integrated research environments, which include multifunctional laboratories, vivariums, and pilot-scale manufacturing suites. The company provides enterprise-grade facilities that cater to organizations of all sizes, facilitating the acceleration of scientific discovery and the development of effective therapeutics. By colocating research and development infrastructure with manufacturing solutions, SmartLabs enhances collaboration among stakeholders in the research and development sector. This unique approach allows companies to initiate, expand, and adapt their programs and projects as needed, ultimately contributing to a more efficient pathway for bringing innovative medical solutions to market.

Checkerspot, Inc. is a biotechnology company based in Berkeley, California, established in 2016. The company specializes in creating performance materials derived from microalgae, focusing on sustainable and high-performance applications. Checkerspot employs advanced techniques in molecular foundry, chemistry, material science, and fabrication technology to develop innovative products, including polyurethanes and textile finish materials. By leveraging the power of biotechnology, Checkerspot aims to expand the range of molecular building blocks available for various industrial applications, providing industries with access to a new generation of sustainable materials.

Sonendo, Inc. is a medical technology company based in Laguna Hills, California, specializing in innovative solutions for root canal therapy. Founded in 2006, the company has developed the GentleWave System, a technology platform that enhances the cleaning and disinfection of tooth structures without compromising integrity. This system significantly improves clinical outcomes and practice efficiency compared to traditional root canal methods. In addition to its product offerings, Sonendo is the parent company of TDO Software, which provides widely used practice management software for endodontic professionals. The software integrates various functionalities, including imaging and communication tools, to streamline practice workflows. Through its focus on advanced dental technologies, Sonendo aims to address the global challenge of tooth decay, ultimately promoting better dental health.

Dren Bio is a biotechnology company that specializes in protein engineering technologies designed to target and deplete pathogenic cells, protein aggregates, and other disease-causing agents. With a focus on hematologic neoplasms, solid cancers, autoimmune disorders, and diseases related to protein aggregation, the company aims to provide innovative solutions for healthcare professionals in their efforts to combat various serious diseases. Operating under a holding company model, Dren Bio develops multiple projects as standalone assets, seeking to create value through its diverse portfolio of biotechnology initiatives.

Starry, Inc. is an innovative internet company headquartered in Boston, Massachusetts, with operations in New York, New York. Founded in 2014, the company specializes in user-friendly Wi-Fi products and high-speed broadband internet services. Starry's flagship product, the Starry Station, is the world's first ambient touchscreen Wi-Fi router, designed to give users enhanced visibility and control over their home networks through an intuitive interface. The company utilizes advanced wideband hybrid-fiber fixed wireless technology to provide gigabit-capable internet without the constraints of bundles, data caps, or long-term contracts. Starry is committed to prioritizing customer needs, promoting digital equity, and ensuring privacy while delivering fast and reliable internet connectivity. Its products are available for purchase on the company's website and are also offered for pre-order through Amazon Launchpad.

Beta Bionics is a biotechnology company focused on developing an integrated bionic pancreas system known as the iLet. This innovative device aims to alleviate the challenges and costs associated with diabetes care by providing a dual-chamber infusion pump that delivers insulin and glucagon with precision. The iLet autonomously calculates and administers the necessary doses, enabling patients to effectively manage their blood sugar levels. The system has received breakthrough designation for all its configurations, including insulin-only, glucagon-only, and bihormonal options, and is compatible with Zealand Pharma’s dasiglucagon, a glucagon analogue known for its stability in a ready-to-use aqueous solution. Through this technology, Beta Bionics seeks to improve the quality of life for individuals living with diabetes.

Simcha Therapeutics is a biopharmaceutical company focused on developing engineered cytokine immunotherapies for cancer treatment. Based in New Haven, Connecticut, the company employs directed evolution to create novel cytokines aimed at enhancing the immune system's ability to combat diseases. Its lead program, ST-067, is a designer IL-18 cytokine that has demonstrated significant antitumor activity in animal studies, both as a standalone treatment and in combination with anti-PD-1 checkpoint inhibitors. Founded in 2018, Simcha Therapeutics is dedicated to advancing innovative therapies that empower patients to effectively fight cancer.

Big Health is a digital therapeutics company headquartered in London, United Kingdom, that specializes in developing and marketing innovative behavioral health programs. The company's flagship product, Sleepio, is a digital sleep improvement program that employs Cognitive Behavioral Therapy techniques to address and personalize sleep disorders. By offering a fully automated healthcare portal, Big Health delivers highly personalized digital therapeutics and behavioral programs aimed at tackling various mental health issues. Their approach combines medical consultation with user-friendly technology, enabling individuals to effectively manage and overcome sleep-related disorders in an efficient manner.

Semasio GmbH, founded in 2010 and headquartered in Hamburg, Germany, specializes in user intelligence and targeting solutions for digital advertising. The company leverages statistical modeling and machine learning to provide a platform that helps marketers build detailed user profiles and identify target groups. Semasio's offerings include Audience Targeting, Contextual Targeting, and Brand Fit Targeting, utilizing Natural Language Processing to analyze website content and create comprehensive profiles for both websites and users. This enables clients, including global agency networks and advertisers, to strategically address specific audiences and optimize their advertising efforts. Additionally, Semasio's technology allows for precise control over the contextual placements of online advertising content, ensuring relevance and efficiency. With development centers in Denmark and Portugal, Semasio is dedicated to enhancing the effectiveness of programmatic advertising in a privacy-conscious environment.

SmartLabs specializes in designing, building, and operating integrated research environments, which include multifunctional laboratories, vivariums, and pilot-scale manufacturing suites. The company provides enterprise-grade facilities that cater to organizations of all sizes, facilitating the acceleration of scientific discovery and the development of effective therapeutics. By colocating research and development infrastructure with manufacturing solutions, SmartLabs enhances collaboration among stakeholders in the research and development sector. This unique approach allows companies to initiate, expand, and adapt their programs and projects as needed, ultimately contributing to a more efficient pathway for bringing innovative medical solutions to market.

Ginkgo Bioworks is a biotechnology firm based in Boston, Massachusetts, that specializes in designing, engineering, and developing custom microbes and organisms for various applications. Founded in 2008, the company focuses on discovering and licensing molecules used in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. In addition to these capabilities, Ginkgo Bioworks provides probiotic bacteria that help protect against infections and creates extensive libraries of molecules. The firm operates across multiple markets, including cultured ingredients, carbon mitigation, probiotics, and natural product discovery. It has reorganized its operations into two primary segments: Cell Engineering and Biosecurity, with a significant portion of its revenue generated from biosecurity-related data analytics and services.

Frontier Medicines Corporation is a pre-clinical stage biopharmaceutical company based in South San Francisco, California, founded in 2018. The company focuses on the discovery and development of medicines targeting cancer-causing proteins through its innovative chemoproteomics platform. This platform utilizes advanced computational methods and machine learning to identify and pharmacologically target new binding pockets on proteins, facilitating the development of small-molecule drugs. By enhancing the accessibility of these proteins, Frontier Medicines aims to provide effective treatments that can redefine the management of debilitating diseases.

Tvardi Therapeutics, Inc. is a biotechnology company based in Houston, Texas, focused on developing innovative medicines for cancer, chronic inflammation, and fibrosis. Founded in 2017, the company specializes in small molecule inhibitors targeting STAT3, a regulatory protein involved in the progression of various cancers and fibrotic diseases. Tvardi's pipeline includes TTI-101, an oral small-molecule STAT3 inhibitor, and an intravenous formulation for non-cancer indications, as well as TTI-102, another oral candidate with potential in STAT3 inhibition. By addressing the underlying mechanisms of disease, Tvardi Therapeutics aims to provide effective treatments for patients suffering from diverse conditions, including breast and lung cancer, as well as chronic inflammatory and fibrotic diseases.

Latch is a technology company that provides an operating system for modern buildings, comprising software, products, and services. Its primary offering is a keyless entry security system, enabling residents and authorized visitors to access doors within apartment buildings using their smartphones. Latch operates across North America, serving both large-scale real estate developers and local property owners, with its solutions deployed in various types of properties, from affordable housing to luxury towers.

Binx Health Limited is an in vitro diagnostics company based in Trowbridge, United Kingdom, focused on developing point-of-care diagnostic solutions for infectious diseases. Established in 2005, the company offers the binx io system, a FDA-cleared and CLIA-waived platform that detects sexually transmitted infections, including chlamydia and gonorrhea, delivering results comparable to central lab performance within approximately thirty minutes. Additionally, Binx Health provides the Callisto system, which meets various throughput requirements for testing in decentralized and near-patient settings. The company's innovative approach aims to enhance access to healthcare by overcoming traditional barriers and improving patient experiences through rapid polymerase chain reaction (PCR)-based testing and a comprehensive digital program that includes counseling and follow-up care. Binx Health has also formed a strategic partnership with Sherlock Biosciences to further advance its capabilities in diagnostics.

Absci is a drug and target discovery company that leverages deep learning AI and synthetic biology to enhance the therapeutic potential of proteins. Its Integrated Drug Creation Platform streamlines the process of identifying novel drug targets, discovering optimal biotherapeutic candidates, and generating the necessary cell lines for manufacturing. By combining biologic drug discovery and cell line development into a single, efficient workflow, Absci collaborates with biotech and pharmaceutical innovators to develop next-generation protein-based drugs. These innovations include Bionic Proteins, which feature nonstandard amino acids, and other unique drug designs that may be unattainable through conventional methods. Absci's mission is to facilitate the development of improved medicines by effectively translating innovative ideas into viable drugs.

Neurogene Inc., established in 2018 and headquartered in New York, specializes in developing genetic medicines for treating neurological disorders. The company focuses on utilizing adeno-associated virus (AAV) vectors to deliver therapeutic genes for conditions such as Charcot-Marie Tooth disease type 4J (CMT4J), Aspartylglucosaminuria (AGU), and an undisclosed Lysosomal Storage Disease (LSD). Neurogene aims to provide effective treatment options where none currently exist, aiming to improve the quality of life for patients and families affected by these rare neurological disorders.

Adagio Medical specializes in the design and manufacture of medical devices aimed at treating cardiac arrhythmias. Founded in 2011 and based in Laguna Hills, California, the company is dedicated to the research and development of innovative cryoablation catheters. These devices are engineered to create safe, continuous, transmural lesions that effectively address various cardiac conditions, including paroxysmal and persistent atrial fibrillation, atrial flutter, and ventricular tachycardia. Adagio Medical's product offerings include the continuous lesion ablation system (iCLAS), specialized catheters, esophageal balloons, and consoles, all developed to enhance the capabilities of electrophysiologists in the treatment of cardiovascular diseases.

Absci is a drug and target discovery company that leverages deep learning AI and synthetic biology to enhance the therapeutic potential of proteins. Its Integrated Drug Creation Platform streamlines the process of identifying novel drug targets, discovering optimal biotherapeutic candidates, and generating the necessary cell lines for manufacturing. By combining biologic drug discovery and cell line development into a single, efficient workflow, Absci collaborates with biotech and pharmaceutical innovators to develop next-generation protein-based drugs. These innovations include Bionic Proteins, which feature nonstandard amino acids, and other unique drug designs that may be unattainable through conventional methods. Absci's mission is to facilitate the development of improved medicines by effectively translating innovative ideas into viable drugs.

Shift is an online marketplace specializing in the buying and selling of used cars. The company acts as a personal concierge service, handling tasks such as detailing cars, listing them on multiple platforms, arranging test drives, and finding interested buyers. Shift charges customers a service fee for registration, car preparation services, and sales tax. Before purchase, customers receive a comprehensive 150-point concierge report that includes vehicle specifications, high-resolution photos, vehicle history, and inspection results.

Xometry Inc. is a provider of on-demand manufacturing services, specializing in various advanced production techniques, including 3D printing, CNC machining, injection molding, and urethane casting. Established in 2013 and headquartered in Gaithersburg, Maryland, with an additional office in Bethesda, the company operates an AI-enabled marketplace that facilitates the efficient sourcing of custom-manufactured parts and assemblies. Xometry's diverse offerings include rapid prototyping, volume production, mechanical assembly, and aftermarket solutions, catering to a wide range of clients, including engineers, product designers, and business owners. The company has a strategic partnership with Roush Yates Manufacturing Solutions, further enhancing its capabilities in the manufacturing sector. Xometry is organized into U.S. and International segments, with the majority of its revenue generated from the U.S. market.

Evolve is a hospitality company with a mission to make renting a vacation home easy for both guests and homeowners. They help guests rest easy knowing our homes are verified, our support is 24/7, and if their stay doesn’t meet our standards, we’ll make it right. We also make vacation rental stress-free for homeowners, partnering with them to book more and keep more of what they earn thanks to our industry-low 10% management fee.

Lyra Therapeutics, Inc. is a clinical-stage therapeutics company that specializes in developing and commercializing innovative drug and delivery solutions for the localized treatment of ear, nose, and throat diseases. Utilizing its proprietary XTreo technology platform, the company aims to deliver medications directly to affected tissues for extended periods with a single administration. Its lead product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed for non-invasive in-office procedures, providing up to six months of continuous drug therapy specifically for chronic rhinosinusitis. The active ingredient in these formulations is mometasone furoate, which is recognized for its efficacy and safety in various FDA-approved therapies. Founded in 2005 and headquartered in Watertown, Massachusetts, Lyra Therapeutics was formerly known as 480 Biomedical, Inc. before rebranding in July 2018.

SmartLabs specializes in designing, building, and operating integrated research environments, which include multifunctional laboratories, vivariums, and pilot-scale manufacturing suites. The company provides enterprise-grade facilities that cater to organizations of all sizes, facilitating the acceleration of scientific discovery and the development of effective therapeutics. By colocating research and development infrastructure with manufacturing solutions, SmartLabs enhances collaboration among stakeholders in the research and development sector. This unique approach allows companies to initiate, expand, and adapt their programs and projects as needed, ultimately contributing to a more efficient pathway for bringing innovative medical solutions to market.

ArcherDX, Inc. is a genomics company headquartered in Boulder, Colorado, specializing in the development and commercialization of advanced genetic analysis products. Established in 2013, the company focuses on next-generation sequencing technologies to enhance genetic mutation detection, particularly in oncology. ArcherDX offers a range of research-use-only products, including DNA-based VariantPlex, RNA-based FusionPlex, and ctDNA-based LiquidPlex assays. These products enable laboratories to conduct genomic analyses for therapy optimization and cancer monitoring. Additionally, ArcherDX provides customized assay design services for clinical and biopharmaceutical clients, allowing them to target specific biomarkers and develop new applications. The company aims to deliver actionable genomic information for the treatment of solid tumors, blood cancers, and sarcomas, catering to academic laboratories, biopharmaceutical firms, and contract research organizations. ArcherDX also seeks regulatory approval for various companion diagnostic assays to further support precision medicine initiatives.

Beta Bionics is a biotechnology company focused on developing an integrated bionic pancreas system known as the iLet. This innovative device aims to alleviate the challenges and costs associated with diabetes care by providing a dual-chamber infusion pump that delivers insulin and glucagon with precision. The iLet autonomously calculates and administers the necessary doses, enabling patients to effectively manage their blood sugar levels. The system has received breakthrough designation for all its configurations, including insulin-only, glucagon-only, and bihormonal options, and is compatible with Zealand Pharma’s dasiglucagon, a glucagon analogue known for its stability in a ready-to-use aqueous solution. Through this technology, Beta Bionics seeks to improve the quality of life for individuals living with diabetes.

Inhibrx, Inc. is a clinical-stage biotechnology company based in La Jolla, California, dedicated to developing a diverse pipeline of novel biologic therapeutic candidates. The company employs advanced protein engineering techniques, including its proprietary sdAb platform, to target complex disease biology, with a focus on oncology, orphan diseases, and infectious diseases. Inhibrx's lead candidates include INBRX-109, a multivalent agonist in Phase 1 trials for solid tumors; INBRX-105, an antagonist of PD-L1 also in Phase 1 trials; INBRX-101, an Fc-fusion protein for alpha-1 antitrypsin deficiency; and INBRX-103, a monoclonal antibody targeting CD47. Additionally, the company is developing preclinical programs such as INBRX-106, an agonist of OX40, and INBRX-111, an antibody targeting Pseudomonas aeruginosa. Inhibrx has established collaborations with organizations like Celgene and Bluebird Bio and has received funding from various granting agencies, including the NIH and CARB-X.

Pulmonx Corporation is a medical technology company specializing in minimally invasive solutions for the diagnosis and treatment of chronic obstructive pulmonary disease (COPD), particularly severe emphysema. Its primary offerings include the Zephyr Endobronchial Valve, designed for patients with hyperinflation due to emphysema, as well as the Chartis Pulmonary Assessment System, which assesses collateral ventilation, and the StratX Lung Analysis Platform, a cloud-based service that analyzes computed tomography data to identify suitable treatment areas. Pulmonx aims to improve the quality of life for patients who remain symptomatic despite medical management and may not be candidates for surgical interventions. The company has received FDA pre-market approval for the Zephyr Valve and has established a global presence, serving markets in the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. Founded in 1995 and headquartered in Redwood City, California, Pulmonx has become a leader in interventional procedures for COPD, supported by extensive clinical evidence demonstrating the effectiveness of its technologies.

SpringWorks Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing medicines for underserved patient populations affected by rare diseases and cancer. The company employs a precision medicine approach and has a diverse portfolio of small molecule targeted oncology products. Its lead candidate, nirogacestat, an oral gamma secretase inhibitor, is currently in Phase III clinical trials for desmoid tumors. Additionally, SpringWorks is advancing several other product candidates, including mirdametinib, an oral MEK inhibitor in Phase IIb trials for neurofibromatosis type 1-associated plexiform neurofibromas, and various combinations involving nirogacestat for multiple myeloma. The company has established collaborations with organizations such as BeiGene, GlaxoSmithKline, and Allogene, aimed at enhancing the development of its therapies. Founded in 2017 and headquartered in Stamford, Connecticut, SpringWorks is committed to unlocking the potential of its pipeline to provide innovative solutions for patients suffering from cancer and rare diseases.

Beta Bionics is a biotechnology company focused on developing an integrated bionic pancreas system known as the iLet. This innovative device aims to alleviate the challenges and costs associated with diabetes care by providing a dual-chamber infusion pump that delivers insulin and glucagon with precision. The iLet autonomously calculates and administers the necessary doses, enabling patients to effectively manage their blood sugar levels. The system has received breakthrough designation for all its configurations, including insulin-only, glucagon-only, and bihormonal options, and is compatible with Zealand Pharma’s dasiglucagon, a glucagon analogue known for its stability in a ready-to-use aqueous solution. Through this technology, Beta Bionics seeks to improve the quality of life for individuals living with diabetes.

Lyra Therapeutics, Inc. is a clinical-stage therapeutics company that specializes in developing and commercializing innovative drug and delivery solutions for the localized treatment of ear, nose, and throat diseases. Utilizing its proprietary XTreo technology platform, the company aims to deliver medications directly to affected tissues for extended periods with a single administration. Its lead product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed for non-invasive in-office procedures, providing up to six months of continuous drug therapy specifically for chronic rhinosinusitis. The active ingredient in these formulations is mometasone furoate, which is recognized for its efficacy and safety in various FDA-approved therapies. Founded in 2005 and headquartered in Watertown, Massachusetts, Lyra Therapeutics was formerly known as 480 Biomedical, Inc. before rebranding in July 2018.

Evolve is a hospitality company with a mission to make renting a vacation home easy for both guests and homeowners. They help guests rest easy knowing our homes are verified, our support is 24/7, and if their stay doesn’t meet our standards, we’ll make it right. We also make vacation rental stress-free for homeowners, partnering with them to book more and keep more of what they earn thanks to our industry-low 10% management fee.

Ascentage Pharma Group International is a clinical-stage biotechnology company focused on developing novel small-molecule therapies for cancer, hepatitis B virus (HBV), and age-related diseases. Founded in 2009 and headquartered in Suzhou, China, the company has established a diverse pipeline of drug candidates, including HQP1351, a BCR-ABL/KIT inhibitor targeting resistant mutations, and APG-2575, an orally administered Bcl-2 selective inhibitor for hematologic malignancies. Additional candidates include APG-1252, aimed at restoring apoptosis in various solid tumors, and APG-115, which targets the MDM2-p53 interaction in solid tumors and lymphoma. Ascentage Pharma also develops APG-1387 for advanced solid tumors and chronic HBV infection, alongside other therapies for non-small-cell lung carcinoma and chronic lymphocytic leukemia. The company has entered into clinical collaborations to explore innovative treatment combinations, furthering its commitment to addressing challenging diseases in the oncology landscape.

Convene LLC is a company that specializes in designing and servicing workspaces, meeting areas, and event venues. Founded in 2009 and headquartered in New York, it operates a network of co-working office spaces that cater to businesses and organizations. Convene offers a comprehensive suite of services, including conference rooms, event spaces, and dining options, supported by advanced technology for in-house production. The company combines elements of design, technology, and hospitality to create inspiring environments for collaboration and productivity. By providing end-to-end conference and collaboration services, Convene enables startups and established businesses to access well-equipped co-working spaces seamlessly.

Metacrine, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, dedicated to developing innovative therapies for liver and gastrointestinal diseases. The company is advancing its lead programs, which target the farnesoid X receptor (FXR), a key drug target in these conditions. Currently, MET409 is undergoing a Phase Ib proof-of-concept clinical trial for patients with non-alcoholic steatohepatitis, while MET642 is in a Phase 1 clinical trial for the same patient population. In addition to its FXR-focused programs, Metacrine is exploring a pipeline of novel drug candidates through its internal research and development capabilities. The company also collaborates with Novo Nordisk A/S to further research related to fibroblast growth factor 1. Metacrine was founded in 2014 and is committed to addressing unmet medical needs in liver and gastrointestinal health.

Kodiak Sciences Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for retinal diseases. The company's leading candidate, KSI-301, is a vascular endothelial growth factor (VEGF)-biological agent currently undergoing Phase 1b clinical trials for the treatment of wet age-related macular degeneration and diabetic retinopathy. Additionally, Kodiak is advancing KSI-501, a bispecific anti-interleukin 6/VEGF bioconjugate aimed at addressing inflammation and abnormal blood vessel growth associated with retinal vascular diseases, which is in the preclinical stage. The company's early research pipeline also includes KSI-601, a triplet inhibitor targeting dry AMD. Founded in 2009 and headquartered in Palo Alto, California, Kodiak Sciences was previously known as Oligasis, LLC before its name change in 2015.

Moderna, Inc. is a biotechnology company established in 2010 and headquartered in Cambridge, Massachusetts. The company specializes in developing therapeutics and vaccines using messenger RNA (mRNA) technology, which provides instructions for cells to produce proteins essential for various biological functions. Moderna has a diverse pipeline, with numerous programs targeting infectious diseases, immuno-oncology, rare diseases, and cardiovascular conditions. As of September 2024, it has 40 mRNA development candidates in clinical trials across multiple therapeutic areas. The company's mRNA technology gained significant recognition with the authorization of its COVID-19 vaccine in December 2020. Moderna maintains strategic alliances with various organizations, including major pharmaceutical companies and research institutions, to enhance its research and development efforts.

Kiniksa Pharmaceuticals, Ltd. is a clinical-stage biopharmaceutical company dedicated to discovering, acquiring, developing, and commercializing therapeutic medicines for patients with debilitating diseases that have significant unmet medical needs. The company has a diverse pipeline of clinical-stage product candidates, including Rilonacept, which is undergoing Phase III trials for recurrent pericarditis; Mavrilimumab, a monoclonal antibody in Phase II trials for giant cell arteritis; and KPL-716, currently in Phase 2a trials for prurigo nodularis and Phase 1a trials for atopic dermatitis. Kiniksa also has preclinical candidates, such as KPL-404, which targets the CD40/CD40L interaction in immune responses. Additionally, the company is collaborating with Kite Pharma to explore the combination of Yescarta and Mavrilimumab in patients with relapsed or refractory Large B-Cell lymphoma. Founded in 2015 and headquartered in Hamilton, Bermuda, Kiniksa Pharmaceuticals aims to address multiple autoimmune and autoinflammatory conditions through its innovative approaches.

Centrexion Therapeutics Corporation is a late clinical-stage biopharmaceutical company based in Boston, Massachusetts, dedicated to developing non-opioid and non-addictive therapies aimed at addressing chronic pain. The company's product pipeline includes CNTX-4975, currently in Phase III trials for moderate to severe knee osteoarthritis pain, and in Phase II trials for Morton’s neuroma and canine osteoarthritis. Additionally, CNTX-0290 is in Phase I trials targeting chronic pain associated with inflammatory, neuropathic, and mixed conditions. Other candidates under development include CNTX-6970, for inflammatory pain, and CNTX-2022, a high-concentration topical gel formulation of lidocaine for various types of pain. CNTX-6016 is also in pre-clinical stages focusing on chronic neuropathic pain. Founded in 2013, Centrexion Therapeutics aims to provide safe and effective solutions for patients suffering from chronic pain conditions.

NexImmune, Inc. is a clinical-stage biopharmaceutical company based in Gaithersburg, Maryland, specializing in the development of innovative immuno-therapeutics utilizing its proprietary Artificial Immune (AIM) technology. This technology is designed to enhance the immune system's ability to generate specific responses to targeted antigens, which is crucial for effective cancer treatment and other immune-mediated diseases. NexImmune's product offerings include AIM101, an injectable therapy for certain solid tumors, and AIM ACT, an adoptive cellular therapy aimed at treating specific hematological malignancies. The company is currently advancing two product candidates in human trials: NEXI-001 for acute myeloid leukemia and NEXI-002 for multiple myeloma. By focusing on improving the body's T cell responses, NexImmune aims to provide curative therapies for patients facing life-threatening conditions.

Neon Therapeutics is a clinical-stage biopharmaceutical company specializing in neoantigen-targeted therapies aimed at advancing cancer treatment. By focusing on the immune system's response to neoantigens, the company seeks to develop innovative therapies that enhance the body's ability to fight cancer. Its product pipeline includes NEO-PV-01, NEO-PTC-01, and NEO-SV-01, which are designed to leverage the unique characteristics of neoantigens to improve patient outcomes.

Intersection is an experience-driven out-of-home media and technology company focused on enhancing urban environments through innovative programming, consumer amenities, and advertising solutions. The company provides content, interactive services, and data-driven advertising in public spaces, aiming to engage individuals by offering connectivity, information, and relevant content. Intersection's offerings are designed to elevate the urban experience, enabling clients to effectively reach and connect with audiences in real-world contexts. Through its approach, Intersection inspires and engages city dwellers throughout their daily activities.

Convene LLC is a company that specializes in designing and servicing workspaces, meeting areas, and event venues. Founded in 2009 and headquartered in New York, it operates a network of co-working office spaces that cater to businesses and organizations. Convene offers a comprehensive suite of services, including conference rooms, event spaces, and dining options, supported by advanced technology for in-house production. The company combines elements of design, technology, and hospitality to create inspiring environments for collaboration and productivity. By providing end-to-end conference and collaboration services, Convene enables startups and established businesses to access well-equipped co-working spaces seamlessly.

Mersana Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of antibody-drug conjugates (ADCs) for cancer treatment. The company utilizes its proprietary biodegradable polymer platform, Dolaflexin, to create a pipeline of ADC product candidates aimed at addressing oncology indications with significant unmet needs. Its lead candidate, XMT-1536, is currently in Phase I clinical trials targeting NaPi2b for the treatment of ovarian cancer, non-small cell lung cancer, and other rare conditions. Mersana is also advancing additional candidates, including XMT-1660, targeting B7-H4, and XMT-2056, a STING agonist ADC, both designed to improve tolerability and therapeutic outcomes. The company has established strategic partnerships with Merck KGaA and Asana BioSciences to further develop its ADC candidates. Founded in 2005, Mersana Therapeutics aims to deliver innovative treatments to patients through its advanced research and development efforts.

Convene LLC is a company that specializes in designing and servicing workspaces, meeting areas, and event venues. Founded in 2009 and headquartered in New York, it operates a network of co-working office spaces that cater to businesses and organizations. Convene offers a comprehensive suite of services, including conference rooms, event spaces, and dining options, supported by advanced technology for in-house production. The company combines elements of design, technology, and hospitality to create inspiring environments for collaboration and productivity. By providing end-to-end conference and collaboration services, Convene enables startups and established businesses to access well-equipped co-working spaces seamlessly.

Twilio is a cloud-based communications company that empowers developers and businesses to build and integrate voice, video, messaging, and authentication into their applications via a robust set of APIs. By merging cloud computing, web services, and telecommunications, Twilio is transforming traditional telecom, enabling more contextual and personalized customer interactions. The company's Super Network ensures fast, cost-effective communication across the globe.

MarkLogic Corporation is a global enterprise software company specializing in data integration and management. It offers a unified NoSQL database platform that ingests, harmonizes, and analyzes complex data from diverse sources, enabling organizations to gain insights faster. The company's flagship product, MarkLogic Data Hub, simplifies data integration, reduces costs, and enhances agility. MarkLogic serves a wide range of industries, including finance, healthcare, government, and media, with clients such as major banks, pharmaceutical companies, and U.S. government agencies. Headquartered in San Carlos, California, MarkLogic has offices worldwide.

Sapphire Energy, Inc. is a San Diego-based company that specializes in producing renewable solutions from algae, pioneering the Green Crude industry. Founded in 2007, the company utilizes sunlight, carbon dioxide, non-potable water, and non-arable land to cultivate algae in outdoor ponds. This biomass can be converted into high-value products, including oils, aquaculture feeds, animal feeds, and fuels, without relying on food crops or potable water. Sapphire Energy's innovative processes not only enhance and replace traditional petroleum-based products but also operate compatibly with existing infrastructure, offering a low carbon and scalable alternative to conventional biofuels. The company has established a research and development facility in Las Cruces, New Mexico, and is developing an Integrated Algal BioRefinery in Columbus, New Mexico, to further its mission of creating sustainable energy solutions.